Glaukos Corporation (GKOS)
GKOSNYSEMedical/Dental Instruments
$236.19
-2.55 (-1.07%) today
At the close, Nov 10, 4:00 PM ET. After hours $236.19 -0.01%
- Market cap
- $13.98bn
- P/E
- –
- EPS, last 4 quarters
- $-0.1300
- Dividend yield
- –
- Day range
- $235.24 to $241.34
- 52-week range
- $83.78 to $255.19
- Average volume
- 616.9k
- Previous close
- $238.74
Analysts
11 coveringBuy10 buy, 1 hold, 0 sell
Targets a year out average $237.82, +0.7% from here
Earnings
next estimate $0.3800Next report
Dec 2025
-27.3%
Mar 2026
+40.0%
Jun 2026
+50.0%
Sep 2026
+491.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $143.12m | $150.57m | $185.61m | $211.03m |
| Gross profit | -$1.52m | $117.23m | $151.59m | $179.87m |
| Operating income | -$139.87m | -$19.86m | -$17.27m | $828.0k |
| Net income | -$133.66m | -$19.78m | -$18.38m | $2.02m |
Last four quarters: revenue $690.33m, margin -24.6%, free cash flow $36.02m
News
8 latest- GEHC Expands Vscan Air AI Capabilities With Lung Guidance & AutoASZacks · 3 hours ago
- Waters Expands Proteomics Reach With MOBILion Systems AcquisitionZacks · 1 day ago
- Glaukos Corporation Outlines Product Roadmap and Commercial Updates in November 2026 Investor PresentationFintel · 4 days ago
- 10x Genomics Launches Sentira AI Tool to Simplify Cell AnalysisZacks · 4 days ago
- Here's Why You Should Retain MMSI Stock in Your Portfolio for NowZacks · 4 days ago
- HIMS' Q3 Earnings: Can Weight Loss Momentum Drive Performance?Zacks · 4 days ago
- XRAY Stock Declines as Q3 Earnings & Sales Miss Estimates, Outlook CutZacks · 4 days ago
- ISRG System Placements Rise 28%: Is Capital Equipment Demand Rising?Zacks · 5 days ago
The company
Glaukos ( www.glaukos.com ) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NYSE
- Region
- North America
- Website
- glaukos.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.